Pravin Dugel Sells 124,882 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 124,882 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $9.04, for a total value of $1,128,933.28. Following the transaction, the insider directly owned 3,033,078 shares of the company’s stock, valued at approximately $27,419,025.12. The trade was a 3.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ocular Therapeutix Stock Down 1.6%

OCUL opened at $6.88 on Thursday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. The company has a market capitalization of $1.50 billion, a PE ratio of -4.78 and a beta of 0.90. The stock’s fifty day moving average is $11.04 and its 200-day moving average is $11.74. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter last year, the business posted ($0.29) earnings per share. The company’s quarterly revenue was down 22.4% on a year-over-year basis. On average, equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Institutional Trading of Ocular Therapeutix

Several hedge funds and other institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its stake in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,242 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Ocular Therapeutix by 1.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,618 shares of the biopharmaceutical company’s stock valued at $674,000 after purchasing an additional 1,314 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 1,392 shares in the last quarter. Trust Co. of Vermont boosted its holdings in shares of Ocular Therapeutix by 24.3% during the fourth quarter. Trust Co. of Vermont now owns 8,950 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,750 shares during the period. Finally, Profund Advisors LLC boosted its holdings in shares of Ocular Therapeutix by 9.9% during the third quarter. Profund Advisors LLC now owns 25,178 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 2,272 shares during the period. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on OCUL. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Thursday, February 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a report on Monday, December 8th. Finally, Chardan Capital reissued a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.00.

Trending Headlines about Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 (AXPAXLI) showed statistical superiority on the trial’s primary vision endpoint versus Regeneron’s Eylea in the Phase 3 SOL‑1 study, validating Ocular’s pathway toward an FDA submission and potential commercial opportunity in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: An analyst reaffirmation and bullish price target — Chardan Capital reissued a “buy” with a $21 target — gives investors a sizable upside thesis should regulatory and commercial questions be resolved. Benzinga
• Neutral Sentiment: Ocular released topline SOL‑1 results and management commentary; while topline reads positive, investors are awaiting full data (subgroup analyses, comparator details, safety, and durability) before repricing longer‑term expectations. Ophthalmology Times
• Negative Sentiment: Market reaction was sharply negative on release day: coverage highlighted the benefit as “modest” and noted that some comparisons used a lower‑dose/less‑favorable Eylea arm, creating doubts about clinical meaningfulness and commercial differentiation. That skepticism appears to have driven heavy selling. MSN article on market reaction
• Negative Sentiment: Significant insider selling was disclosed (including large sales by Pravin Dugel and others, plus Nadia Waheed’s sale), which can amplify downward pressure and signal near‑term insider liquidity actions to the market. SEC filing for insider sales
• Negative Sentiment: Johnson Fistel’s public investor outreach flags an investigation into possible securities claims against Ocular’s officers — news that can increase legal uncertainty and weigh on sentiment until resolved. GlobeNewswire: Johnson Fistel announcement

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.